2973 T3D2931 Almotriptan Almotriptan is an exogenous organic compound with the formula C17H25N3O2S and an average molecular weight of 335.46 g/mol. It exists as a solid at room temperature. Almotriptan belongs to the tryptamines and derivatives, a subclass of indoles and derivatives within the organic compounds. This compound functions as a serotonergic agonist, vasoconstrictor agent, and non-steroidal anti-inflammatory drug. It binds with high affinity to human 5-hydroxytryptamine receptor 1B (HTR1B) and 5-hydroxytryptamine receptor 1D (HTR1D) receptors, which leads to the constriction of cranial blood vessels. The compound is recorded in several sources, including analgesics within healthcare, pharmaceuticals, and veterinary products; electric hearing aids within electrical and electronic equipment; and other smoking requisites and non-electric simulated smoking devices within household cleaning and consumer products. The recorded route of exposure for almotriptan is oral. 181183-52-8 123606 C17H25N3O2S 335.166750 White powder. 1.21e-01 g/L Oral Almotriptan binds with high affinity to human 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors leading to cranial blood vessel constriction. Hepatic. Route of Elimination: Almotriptan is eliminated primarily by renal excretion (about 75% of the oral dose), with approximately 40% of an administered dose excreted unchanged in urine. Approximately 13% of the administered dose is excreted via feces, both unchanged and metabolized. Half Life: 3-4 hours No indication of carcinogenicity to humans (not listed by IARC). Almotriptan is indicated for the acute treatment of migraine with or without aura in adults. [Wikipedia] Nausea, drowsiness, dizziness, diarrhea, headache, sweating, or dry mouth may occur. Gastrointestinal decontamination (i.e., gastric lavage followed by activated charcoal) should be considered in patients suspected of an overdose with Almotriptan. Clinical and electrocardiographic monitoring should be continued for at least 20 hours, even if clinical symptoms are not observed. (L1712) 2009-07-21T20:27:58Z 2026-05-14T16:52:48Z Almotriptan 520985 Almotriptan DB00918 true CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2 C17H25N3O2S InChI=1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 335.464 335.166747749 Exogenous Solid 1.6 HMDB15054 CHEMBL1505 110198 <p>Ramasubramanian Sridharan, Vandanapu Purushotham, Kori Algooram, Nitin Pradhan, &#8220;Crystalline forms of almotriptan and processes for their preparation.&#8221; U.S. Patent US20070112055, issued May 17, 2007.</p> CHEM002302 DTXSID5044289 NS00014315 dimethyl(2-{5-[(pyrrolidine-1-sulfonyl)methyl]-1H-indol-3-yl}ethyl)amine 56.410000000000004 94.52189999999999 37.00585179084725 5 3 1 17.136012780155003 9.545771606171147 1 3 2.04 -3.44 1.21e-01 g/l Organic compounds Organoheterocyclic compounds Indoles and derivatives Tryptamines and derivatives 313 CED0009506 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 40000000000000000008000000001800000000000000000000000000000000000004000000002000080000200080000000000000000000000200008000000000000001000000000004000000000000000280000000004000000000000000000000000000200000000000000001040000000000201000000000000000000000008000000400000000000002000000000001000000000000000000010000000000000000000000000040400000800000000000020000000000880000000000000100080000000000000000000000000000010000000000000000002a0000000000000000000000000000041000000000000005001000010000002000000000000 5002001089128200800007440128600201001400010520042034a240822008cc44860050138008000000410800c00100042000a5808c3201000264f101a04000c6110400129004810090104002ea02000844059055311b3241040c62500000020c3805270048020060000000d7940000208680700111c0041119382826110012024000084ef482080c0622400a2c0008193c0812448014830202080000424084504310000090c00002000960017c2d100ac80000894108481881421008404a12a01000a404903233018004001c11028004010040020050200d400a040800030490104812088102000000001111522080001000308242000e4008100052100042 776t3gAAAAAQAAAAAwAAAAAAAAAXAAAAGQAAAIABBgBgAAAAAQMHACAAAAAD BgBgAAAAAQMGAGAAAAACAgYAYAAAAAICBkAoAAAAAwQGQGgAAAADAwEHQDgA AAADAQMGQCgAAAADBAZAKAAAAAMEBkBoAAAAAwMBBkAoAAAAAwQGAGAAAAAC AhAAIAAAAAYIACgAAAADAggAKAAAAAMCBwAgAAAAAwYAYAAAAAICBgBgAAAA AgIGAGAAAAACAgYAYAAAAAICBkBoAAAAAwMBBkBoAAAAAwMBCwABAAECAAED AAMEAAQFAAUGaAwGB2gMBwhoDAgJaAwJCmgMCgtoDAsMAAwNAA0OCAINDwgC DRAAEBEAERIAEhMAExQACxVoDBUWaAwJBWgMFBAAFghoDEIDAAAABQUGBwgJ BgoLFRYICQUREBQTEhcEAAAAAAAAABY= 2026-09-19T04:00:39Z